Home › Funds › Crossingbridge Advisors, LLC › DMII
Crossingbridge Advisors, LLC position in DMII
DRUGS MADE IN AMER ACQ II CO · Financials
Crossingbridge Advisors, LLC reported holding 1,100,000 shares of DMII (DRUGS MADE IN AMER ACQ II CO) in its Q3 2026 13F filing — a position valued at US$11.2M, representing 2.24% of its reported portfolio and ranking #7 among its reported holdings. Crossingbridge Advisors, LLC has disclosed DMII holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Crossingbridge Advisors, LLC's DMII position evolved
Crossingbridge Advisors, LLC first disclosed a stake in DMII in Q1 2026 at 350,000 shares (US$3.5M). The position peaked in Q3 2026 at 1,100,000 shares, worth US$11.2M. Across 3 filings, Crossingbridge Advisors, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,100,000 shares valued at US$11.2M. Notable position changes include a 214% increase in Q2 2026 (shares rose 1% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 350.00K | $3.49M | New |
| Q2 2026 | 1.10M | $11.07M | Add |
| Q3 2026 | 1.10M | $11.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMII and 13F data
DMII (DRUGS MADE IN AMER ACQ II CO) is a Financials company. 71 other funds we track also report a position in DMII — the largest reported positions include Karpus Management, Inc. (US$28.0M), Magnetar Financial LLC (US$27.5M), MMCAP International Inc. SPC (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMII
- Karpus Management, Inc. 2.79M sh · $28.05M · Q2 2026
- Magnetar Financial LLC 2.70M sh · $27.51M · Q3 2026
- MMCAP International Inc. SPC 2.70M sh · $27.49M · Q3 2026
- GLAZER CAPITAL, LLC 2.34M sh · $23.57M · Q2 2026
- HIGHBRIDGE CAPITAL MANAGEMENT LLC 2.24M sh · $22.57M · Q2 2026
- WOLVERINE ASSET MANAGEMENT LLC 1.84M sh · $18.75M · Q3 2026
- First Trust Capital Management L.P. 1.30M sh · $13.22M · Q3 2026
- Mercuria Capital Strategies, LLC 750.00K sh · $7.63M · Q3 2026
- HEIGHTS CAPITAL MANAGEMENT, INC 519.40K sh · $5.23M · Q2 2026
- TIG Advisors, LLC 500.00K sh · $5.03M · Q2 2026
- Wealthspring Capital LLC 399.15K sh · $4.06M · Q3 2026
- Logan Stone Capital, LLC 381.69K sh · $3.84M · Q2 2026
More on Crossingbridge Advisors, LLC
FAQ
How long has Crossingbridge Advisors, LLC held DMII?
Crossingbridge Advisors, LLC has disclosed DMII holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Crossingbridge Advisors, LLC's current position in DMII?
As of Q3 2026, Crossingbridge Advisors, LLC holds 1.10M shares of DMII (DRUGS MADE IN AMER ACQ II CO), valued at $11.20M, representing 2.24% of its reported portfolio and ranking #7.
Has Crossingbridge Advisors, LLC been buying or selling DMII?
In the latest 13F filing (Q3 2026), Crossingbridge Advisors, LLC held unchanged its position in DMII. The position peaked in Q3 2026 at 1.10M shares.
Which other funds hold DMII?
Other major institutional holders of DMII include Karpus Management, Inc., Magnetar Financial LLC, MMCAP International Inc. SPC, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.